Myocardial cell membrane stress ionic dyskinesia reversal by diltiazem

Om Gomes1, Es Gomes

  • 1São Francisco de Assis Cardiovascular Foundation, Belo Horizonte, Minas Gerais, Brazil.

Insights

Diltiazem, a calcium channel blocker, effectively normalized exercise stress test results in patients with silent myocardial ischemia. This suggests calcium-dependent myocardial contraction plays a role in silent ST segment depression.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Exercise stress testing can induce silent myocardial ischemia.
  • Myocardial stress dyskinesia is a potential cause of this ischemia.
  • Calcium channel blockers may offer a therapeutic approach.

Purpose of the Study:

  • To investigate the efficacy of diltiazem in patients with exercise stress testing-induced silent myocardial ischemia.
  • To explore the role of calcium-dependent myocardial contraction in silent ST segment depression.

Main Methods:

  • A study involving 25 patients with positive ergometric testing but no obstructive coronary artery disease.
  • Patients received diltiazem (90 mg three times daily) and underwent repeat treadmill electrocardiography exercise testing.
  • Key parameters analyzed included ST segment depression, heart rate, and exercise performance.

Main Results:

  • Diltiazem abolished atypical precordial pain in all patients.
  • ST segment depression (both J and Y points) was significantly reduced post-treatment (P<0.001).
  • Functional cardiac classification improved significantly (P<0.01) with diltiazem treatment.

Conclusions:

  • Diltiazem effectively prevented exercise-induced silent ST segment depression in patients without obstructive coronary artery disease.
  • These findings support the involvement of calcium-dependent myocardial contraction dyskinesia in the genesis of silent ST segment depression.

Related Concept Videos

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...